Figures computed from official regulatory filings — .
Analysttarget 35 USD (+71%) · consensus 4.2/5 · 4 buy · 0 hold · 1 sell
Ownershipinsiders 1.01% · institutions 108.87% · short 13.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Innoviva, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
77 buys302 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Zhen Marianne | Other | $23.7K | SEC |
| Raifeld Pavel | Other | $23.7K | SEC |
| Basso Stephen | Other | $11.7K | SEC |
| dEsparbes Eric | Other | $70.8K | SEC |
| GLAXOSMITHKLINE PLCtrack record | Buy | $856.9B | conv 19 | SEC |
| Faerm Michael E. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tyree James L | Sell | $41.1K | SEC |
| Aguiar Michael W | Other | $412K | Unusual size | SEC |
| WALTRIP WILLIAM H | Sell | $266.2K | SEC |
| WALTRIP WILLIAM H | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WALTRIP WILLIAM H | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WALTRIP WILLIAM H | Exercise | $219.4K | SEC |
| Aguiar Michael W | Other | $123.7K | SEC |
| Aguiar Michael W | Other | $52.9K | SEC |
| GLAXOSMITHKLINE PLCtrack record | Buy | $117.2B | conv 9 | SEC |
| Kearney Terrence C | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WALTRIP WILLIAM H | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PEPE PAUL | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tyree James L | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FRIEDMAN CATHYtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GLAXOSMITHKLINE PLCtrack record | Buy | $155.1B | conv 6 | SEC |
| WITEK THEODORE L JR | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| dEsparbes Eric | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aguiar Michael W | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WITEK THEODORE L JR | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |